Qiagen NV, the Netherlands-based holding company for the German diagnostics company of the same name, is offering to buy Ipsogen SA of France in two stages for approximately €70 million starting with the purchase of a 47% stake.
The US Food and Drug Administration has approved a new genetic test that will help physicians to determine if women with human epidermal growth factor Receptor 2-positive (HER2+) breast cancer can benefit from Herceptin (trastuzumab).
The US Food and Drug Administration has approved ezogabine, a potassium channel opener, as an adjunctive treatment for partial-onset seizures in patients 18 years and older. The developers are Valeant Pharmaceuticals and GSK.
The US Food and Drug Administration has approved a new imaging device that enables the simultaneous administration of a positron emission tomography scan (PET) and a magnetic resonance imaging scan (MRI). The device has been developed by Siemens.
CureVac GmbH, which has a messenger RNA vaccine in development for prostate cancer has reported that the vaccine induced an immune response to at least one antigen in 79% of patients in a Phase 1/2a study.
H. Lundbeck A/S has announced the resignation of its executive vice president for commercial operations, Stig Løkke Pedersen, who will pursue new opportunities. The board of directors has begun the recruitment of a successor.
A molecular diagnostic developed by MDxHealth of Belgium will be used to screen patients for a second oncology trial in what is seen as a further expansion of the rapidly evolving field of personalised medicine. The assay tests methylation status.
Pfizer Inc has received institutional review board approval to start a virtual clinical trial in the US that uses mobile telephone and web-based technology to collect data from participants rather than requiring them to visit clinics.
Merck & Co and Austria’s Intercell AG have announced the end of a Phase 2/3 clinical trial of a vaccine for the prevention of Staphylococcus aureus (S. aureus) infection. Trial enrolment had previously been suspended in April.
4SC AG has announced that a Phase 2b trial of its small molecule inhibitor of pro-inflammatory cytokines, vidofludimus, failed to meet its primary endpoint in a Phase 2b trial of patients with rheumatoid arthritis.